Hydrogen’s Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest
Open Access
- 7 November 2025
- journal article
- clinical trial-protocol
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-12
Abstract
Extracorporeal cardiopulmonary resuscitation (ECPR) improves survival for patients experiencing refractory cardiac arrest but is often associated with severe ischemia-reperfusion injury (IRI). Hydrogen gas (H2) has demonstrated promising preclinical efficacy in reducing IRI. The Hydrogen-FAST trial investigates the feasibility and safety of inhaled hydrogen gas as an adjunctive therapy during ECPR in patients with congenital heart disease (CHD). This phase 1 multicenter randomized controlled trial enrolls patients of any age undergoing ECPR due to refractory cardiac arrest associated with underlying cardiac morbidity. Due to the emergent nature of ECPR events, the trial leverages an Exception from Informed Consent enrollment process. Fifty-three participants will be randomized to standard care or standard care plus inhaled 2% H2 gas delivered continuously for 72 h via mechanical ventilator and extracorporeal membrane oxygenation (ECMO) circuit. Primary endpoints include feasibility, measured as the percentage of the first 72 h post-arrest in which hydrogen is successfully administered, with feasibility defined as a mean percentage of ≥90%, and safety, evaluated through incidence rates of treatment-related serious adverse events (SAEs). Secondary endpoints examine clinical outcomes including survival to discharge, ICU length of stay, functional status at 6 months, neurologic function, and markers of ischemic injury. The Hydrogen-FAST trial will provide essential data on the feasibility and safety of H2 administration during ECPR, informing larger efficacy studies and potential broader clinical use in critical care settings. ClinicalTrials.gov NCT05574296. Registered on October 6, 2022. https://clinicaltrials.gov/study/NCT05574296 .Keywords
Funding Information
- National Institute of Child Health and Human Development (5R33HL164373-03, 1R61HL164373-01)
- Mooneyhan Family Foundation
This publication has 18 references indexed in Scilit:
- Combination of Hydrogen Inhalation and Hypothermic Temperature Control After Out-of-Hospital Cardiac Arrest: A Post hoc Analysis of the Efficacy of Inhaled Hydrogen on Neurologic Outcome Following Brain Ischemia During PostCardiac Arrest Care II TrialCritical Care Medicine, 2024
- Public support for and concerns regarding pediatric dose optimization for seizures in emergency medical services: An exception from informed consent (EFIC) trialAcademic Emergency Medicine, 2024
- Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialeClinicalMedicine, 2023
- Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy AdultsCritical Care Explorations, 2021
- Modeling severe functional impairment or death following ECPR in pediatric cardiac patients: Planning for an interventional trialResuscitation, 2021
- Hydrogen gas distribution in organs after inhalation: Real-time monitoring of tissue hydrogen concentration in ratScientific Reports, 2019
- Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and NeuroprotectionJournal of Stroke and Cerebrovascular Diseases, 2017
- Inhaled Hydrogen Gas Therapy for Prevention of Lung Transplant-Induced Ischemia/Reperfusion Injury in RatsTransplantation, 2010
- Hydrogen Inhalation Ameliorates Oxidative Stress in Transplantation Induced Intestinal Graft InjuryAmerican Journal of Transplantation, 2008
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicalsNature Medicine, 2007